#

19-21 SEPTEMBER 2017 //

MARITIM PROARTE HOTEL, BERLIN

Conference

Welcome to the 3rd Annual Phacilitate Cell & Gene Therapy Europe.  

Meet the future of ATMP commercialisation at Europe’s premier partnering event for advancing cell and gene therapy business models

The only European event that offers extensive specific coverage of ATMP R&D, manufacturing and regulatory issues and challenges, whilst also placing these components in their wider strategic context at the core of successful cell & gene therapy business and commercialization models.  

No other cell and gene therapy on the continent draws as many vital stakeholders, including:

  • The EU's leading regulators, HTAs and payers, each providing critical, need-to-know insight for anyone seeking to develop and commercialise ATMPs.  
  • Pharma decision makers actively seeking partnering opportunities in this space. 
  • Investors looking to back European ATMP companies today

10 KEY AGENDA TOPICS:

  • Reviewing significant recent and expected forthcoming events in the ATMP space worldwide – What do they tell us about the relative strengths and weaknesses of the European sector? What are the critical areas of competitive advantage in Europe today? 
  • ATMP market access strategy: how to ensure European patients receive the full benefit from cell, gene and immunotherapy innovation?
  • Highlighting key recent and forthcoming areas of EU regulatory guideline and legislation development – what is ‘need to know’ for the world’s cell & gene therapy industry leaders? 
  • To centralise or decentralise? Examining the full spectrum of potential models available for ATMP manufacturing, from remote facility to point of care – how realistic is each option for commercial scale production in Europe?
  • How to capitalise on Europe’s expedited/accelerated clinical development pathways? And how to ensure your bioprocess development and optimisation stays in step?
  • Upscaling and optimising vector production platforms to meet future ATMP industry demand
  • What will European market access strategy for CAR T cell therapies look like?
  • Effective de-risking strategies around ATMP raw material quality and supply 
  • Harnessing the cutting edge of automation to drive robust, cost effective cell-based therapy manufacturing at commercial scale
  • What do tomorrow’s bioanalytical toolboxes for both cell-based and in vivo gene therapies therapy look like? 

WHERE EUROPE MEETS THE WORLD

Join 400 ATMP industry decision-makers and key external stakeholder leaders at the event which defines the strategic roadmap to success for the world’s cell & gene therapy developers and manufacturers, ensuring European patients gain access to the game-changing biotherapeutics of tomorrow.

cgt

Meet the key senior European executives, as well as the global cell and gene therapy community, with job titles at the 2016 event including:

 

Head of Global Medical Affairs & EU Clinical Development

VP & Head of Gene Therapy Development

SVP, Clinical & Regulatory

VP, Manufacturing

VP, Cell & Gene Therapy Product Development & Supply

Senior Director, Scientific Affairs & Analysis

Global Head of Clinical Development

Chief Executive Officer

Chief Medical Officer

Chief Regulatory & Compliance Officer

Advisory Board

"It was a very interesting event as all participants, including speakers were ready to exchange, even on the most challenging subjects such as reimbursement, GMP guidance."

Bertrand Alexandre, Director, Marketing Europe, Celyad

Sponsors

  • #
  • #
  • #
  • #
  • #
  • #
  • #
  • #
  • #
  • #
  • #
  • #
  • #
  • #
  • #
  • #
  • #
  • #
  • #